Patents Represented by Attorney, Agent or Law Firm Cheryl L. Becker
  • Patent number: 8318897
    Abstract: The present invention is directed to novel polynucleotides and polypeptides directed to EXP1 of Plasmodium vivax, and methods of using these polynucleotides and polypeptides in the detection of P. vivax antibodies or anti-P. vivax antibodies in a subject. The invention finds particular useful application in identifying recent exposure to P. vivax.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: November 27, 2012
    Assignee: Abbott Laboratories
    Inventors: Larry G. Birkenmeyer, Ruthie E. Coffey, George J. Dawson, Suresh M. Desai, Bruce J. Dille, Anthony Scott Muerhoff
  • Patent number: 8304201
    Abstract: The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: November 6, 2012
    Assignee: Abbott Laboratories
    Inventors: Maciej Adamczyk, Roy Jeffrey Brashear, Phillip G. Mattingly
  • Patent number: 8288124
    Abstract: The present invention relates to a new method of producing functionally active recombinant porcine Intrinsic Factor as well as the protein (i.e., porcine Intrinsic Factor) produced thereby. In particular, the vector comprising the DNA encoding the protein is introduced into a Chinese Hamster Ovary (CHO) host cell under conditions sufficient for optimal expression of functional protein. The expressed protein may then be subjected to three methods ultimately resulting in a protein having at least 97% purity.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: October 16, 2012
    Assignee: Abbott Laboratories
    Inventors: Ramani S. Wonderling, John F. Uher, Thomas P. Leary, You Pan
  • Patent number: 8283124
    Abstract: The present invention relates to one or more peptides which may be used to test for the presence of antibodies to B. microti. These peptide are selected based on the strength and specificity of the human antibody response to B. microti. These peptides alone or in combination have a variety of uses, for example, as a component of a diagnostic assay or kit.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: October 9, 2012
    Assignee: Abbott Laboratories
    Inventors: Larry G. Birkenmeyer, Suresh M. Desai, Dinesh O. Shah, Yu Cheng, George J. Dawson
  • Patent number: 8283162
    Abstract: The present invention relates to antibodies that may be used, for example, in the diagnosis, treatment and prevention of haepatocellular carcinoma (HCC), liver cancer and related conditions.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: October 9, 2012
    Assignee: Abbott Laboratories
    Inventors: Toru Yoshimura, Barry L. Dowell, Gangamani S. Beligere, Qiaoqiao Ruan
  • Patent number: 8268981
    Abstract: The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of the Plasmodium species P. malariae and P. ovale. Such genes and proteins have many beneficial diagnostic as well as therapeutic uses.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: September 18, 2012
    Assignee: Abbott Laboratories
    Inventors: Larry G. Birkenmeyer, Anthony S. Muerhoff, Suresh M. Desai, George J. Dawson, Bruce J. Dille
  • Patent number: 8241915
    Abstract: The present invention relates to methods of detecting hemoglobin in a test sample. These methods can be used to diagnose a subject suffering from a genetic disorder relating to hemoglobin metabolism, to determine the eligibility of a subject to be a blood donor, to determine the age of a stored blood sample or to identify a hemolyzed plasma sample. The present invention also relates to kits for use in the above described methods.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: August 14, 2012
    Assignee: Abbott Laboratories
    Inventors: Maciej Adamczyk, Roy J. Brashear, Phillip G. Mattingly
  • Patent number: 8183002
    Abstract: The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: May 22, 2012
    Assignee: Abbott Laboratories
    Inventors: Maciej Adamczyk, Jeffrey R. Brashear, Phillip G. Mattingly
  • Patent number: 8138318
    Abstract: This invention relates to a nucleic acid molecule encoding a middle Hepatitis B virus (HBV) surface protein, a vector comprising the nucleic acid molecule, a host cell comprising the vector, and a composition comprising the expression products of this vector, which may comprise middle HBV surface protein, or a mixture of middle HBV surface protein and small HBV surface protein. The compositions of the invention may be useful for expressing a middle HBV surface protein, or a mixture of small and middle HBV surface proteins in defined ratios, determining the binding of an antibody to a middle or small HBV surface protein, determining the quality of an anti-middle or an anti-small HBV surface protein antibody, or determining the quality of a kit containing anti-middle or anti-small HBV surface protein antibodies.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: March 20, 2012
    Assignee: Abbott Laboratories
    Inventors: Paul F. Coleman, Sandra K. Pearce
  • Patent number: 8063193
    Abstract: The present invention is directed to novel polynucleotides and polypeptides directed to EXP1 of Plasmodium vivax, and methods of using these polynucleotides and polypeptides in the detection of P. vivax antibodies or anti-P. vivax antibodies in a subject. The invention finds particular useful application in identifying recent exposure to P. vivax.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: November 22, 2011
    Assignee: Abbott Laboratories
    Inventors: Larry G. Birkenmeyer, Ruthie E. Coffey, George J. Dawson, Suresh M. Desai, Bruce J. Dille, Anthony S. Muerhoff
  • Patent number: 8030026
    Abstract: The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: October 4, 2011
    Assignee: Abbott Laboratories
    Inventors: Susan E. Brophy, Bailin Tu, Joan D. Tyner, Lowell J. Tyner, legal representative, Dagang Huang, Robert N. Ziemann
  • Patent number: 8030471
    Abstract: The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of the Plasmodium species P. malariae and P. ovale. Such genes and proteins have many beneficial diagnostic as well as therapeutic uses.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: October 4, 2011
    Assignee: Abbott Laboratories
    Inventors: Larry G. Birkenmeyer, Anthony S. Muerhoff, Suresh M. Desai, George J. Dawson, Bruce J. Dille
  • Patent number: 7932369
    Abstract: An isolated nucleotide sequence or fragment thereof encoding the porcine intrinsic factor, wherein the porcine intrinsic factor comprises an amino acid sequence having at least 85% amino acid sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 6, and SEQ ID NO: 9. The invention also encompasses an isolated nucleic acid sequence or fragment thereof comprising, or complementary to, a nucleotide sequence having at least 85% nucleotide sequence identity to a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 4, and SEQ ID NO: 7. The porcine intrinsic factor can be use is an assay to determine the quantity of vitamin B12 in a biological sample.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: April 26, 2011
    Inventors: Ramani S. Wonderling, John F. Uher
  • Patent number: 7901910
    Abstract: A method for expressing a heterologous protein in a prokaryotic host cell, comprising the steps of: (a) providing a DNA vector having: (1) a control region operatively linked to a first genetic element encoding a carrier protein capable of expression in the host cell, and (2) a second genetic element encoding the heterologous protein, the second element being embedded within the first element such that the first and second elements are contiguous and in the same reading frame; (b) transforming the host cell with the DNA vector; and (c) expressing a fusion protein of the heterologous protein and the carrier protein, wherein the heterologous protein is joined at its N-terminus to a first domain of the carrier protein and at its C-terminus to a second domain of the carrier protein, and also a method for confirming intact expression of heterologous proteins, as well as fusion proteins, DNA constructs, plasmid vectors and transformed host cells relating to the above methods.
    Type: Grant
    Filed: November 1, 1996
    Date of Patent: March 8, 2011
    Inventors: Gregory Thomas Maine, Linda Ellen Chovan
  • Patent number: 7824908
    Abstract: The present invention relates to a genetically engineered P30 antigen and a combination or mixture of antigens (e.g., the genetically engineered P30 antigen and P35) that may be used in the detection of IgM and/or IgG antibodies to Toxoplasma gondii. Furthermore, the present invention also relates to methods of using this genetically engineered P30 antigen and combination of antigens, antibodies raised against this genetically engineered P30 antigen and combination of antigens, as well as kits and vaccines containing the genetically engineered P30 antigen and antigens present in the combination.
    Type: Grant
    Filed: September 24, 2007
    Date of Patent: November 2, 2010
    Inventors: Gregory T. Maine, Chandu B. Patel, Sanford R. Ginsburg, Timothy R. Bliese
  • Patent number: 7749717
    Abstract: The present invention relates to the diagnosis of Trypanosoma cruzi infection.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: July 6, 2010
    Assignee: Abbott Laboratories
    Inventors: Dinesh O. Shah, Chi-Deu Chang, Gerald Schochetman, Kevin Y. Cheng
  • Patent number: 7556815
    Abstract: The subject invention relates to a novel hepatitis B surface antigen mutant and methods of detecting this mutant, and/or antibodies thereto, in patient samples. In particular, the mutant contains a substitution of amino acid threonine for the amino acid alanine at position 123 in the amino acid sequence of the hepatitis B surface antigen (HBsAg) protein.
    Type: Grant
    Filed: February 22, 2007
    Date of Patent: July 7, 2009
    Assignee: Abbott Laboratories Inc.
    Inventors: Paul F. Coleman, Isa K. Mushahwar
  • Patent number: 7432046
    Abstract: The present invention relates to methods of determining anti-infectious agent IgG avidity, for example, human anti-cytomegalovirus and human anti-toxoplasma IgG avidity, using a competitive assay format.
    Type: Grant
    Filed: November 2, 2005
    Date of Patent: October 7, 2008
    Assignee: Abbott Laboratories
    Inventors: Gregory T. Maine, Stephen C. Hsu, Darwin D. Smith, Dominick L. Pucci, Jörg Herzogenrath, Ingo Curdt, Heike Maria Christ
  • Patent number: 7393933
    Abstract: A monoclonal antibody that is capable of binding specifically to wild type HBsAg and to at least two mutant forms of HBsAg may be used in an improved immunoassay for the detection of both escape mutants and wild type HBsAg and may be used for passive immunisation against HBV.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: July 1, 2008
    Inventors: Richard Seton Tedder, Samreen Ijaz, Ruth Bridget Ferns
  • Patent number: 7282207
    Abstract: This invention relates generally to a multimeric polypeptide complex/antigen which may be utilized in detecting or diagnosing diseases of the uterus such as uterine cancer. Furthermore, the invention relates to methods and kits, for example, which utilize this antigen or an antibody thereto. The complex itself comprises at least one EU250 polypeptide and at least one polypeptide which may be a BU101 polypeptide and/or a TU104 polypeptide. The complex may further comprise other, as yet unknown, polypeptide sequences.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: October 16, 2007
    Assignee: Abbott Laboratories
    Inventors: Tracey L. Colpitts, John C. Russell